Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCP-25 in Healthy Volunteers, Venous Leg Ulcers, and Dystrophic Epidermolysis Bullosa
NCT05378997Phase 1Completed
- Sponsor
- Xinnate
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Modified Peptides, Recombinant Proteins and Enzymes, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tcp-25 in venous leg ulcer (VLU) and dystrophic epidermolysis bullosa (DEB) (3 arms), sponsored by Xinnate. Primary endpoints: Adverse Events at 15 days, Incidence of abnormal local reactions at Day 15 and 4 more. Started Apr 2022; status: completed.
02
Drugs
tcp-25
03
Conditions
venous leg ulcer (VLU)dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT05378997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378997.